I think FULC is on an edge of a gamma squeeze which will lead to a short squeeze.
There are 61.92M shares outstanding. According to finwiz, insiders own 7.27% and institutions own 92.33% which equals 99.6% ownership and 0.4% shares out there. As of 6-28, short interest was 8.96%. Shorts literally don't have any room out. Fintel estimates that the current short interest is 12.08%. Shorts are fucked.
At the same time, nothing but good news on the company side. They are a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
CEO recently bought stock at US$11.35 per share while the current price is around $9.
https://finance.yahoo.com/news/ceo-president-director-fulcrum-therapeutics-113556250.html
Due to a recent deal with Sanofi, the company estimates a cash runway to 2027. Meaning no dilution anytime soon.
Not to mention that the options chain is currently stacked with 38,852 calls out of the money for Jan 17, 2025
https://chartexchange.com/symbol/nasdaq-fulc/optionchain/summary/
Leave a Reply